BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
- Conditions
- Progressive Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1092
- Registration Number
- NCT06025578
- Locations
- 🇨🇳
Local Institution - 0424, Suzhou Shi, Jiangsu, China
🇧🇪Vzw Az Groeninge, Kortrijk, Belgium
🇵🇱Local Institution - 0187, Lodz, Poland
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT06013995
- Locations
- 🇺🇸
North Georgia Rheumatology, Lawrenceville, Georgia, United States
🇲🇽Local Institution - 0077, Chihuahua, Mexico
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1185
- Registration Number
- NCT06003426
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Local Institution - 0179, Jasper, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 37
- Registration Number
- NCT05985590
- Locations
- 🇨🇦
Local Institution - 0002, Québec, Quebec, Canada
A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants
- Conditions
- Healthy Male Volunteers
- Interventions
- Drug: [14C]-BMS-986196
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT05981963
- Locations
- 🇺🇸
Labcorp Clinical Research Unit - Madison, Madison, Wisconsin, United States
A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- Biological: Abatacept
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 174
- Registration Number
- NCT05981976
- Locations
- 🇺🇸
Local Institution, Las Vegas, Nevada, United States
A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BMS-986419 DR CapsuleDrug: BMS-986419 IR Tablet
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT05963932
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1182
- Registration Number
- NCT05953402
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- Conditions
- Heart Failure With Reduced Ejection Fraction
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT05952089
- Locations
- 🇺🇸
Research Integrity LLC, Owensboro, Kentucky, United States
🇺🇸Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸Sinai Hospital Of Baltimore, Baltimore, Maryland, United States
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 360
- Registration Number
- NCT05949684
- Locations
- 🇺🇸
Community Cancer Institute, Clovis, California, United States
🇺🇸John Muir Medical Center - Concord Campus, Concord, California, United States
🇺🇸Compassionate Cancer Care Medical Group, Fountain Valley, California, United States